Since the discovery of leptin, understanding of the mechanisms that control energy balance has rapidly advanced. Unfortunately, except for leptin replacement therapy in a handful of leptin deficient individuals, there is yet to emerge any interventions that effectively prevent or treat obesity in the general population. Both insulin and leptin are secreted in proportion to body fatness and serve as adiposity signals, acting on the same neurons of the hypothalamic arcuate nucleus to regulate energy homeostasis. Ghrelin, which is secreted by the stomach and duodenum, serves as a hunger signal at the hypothalamus and brainstem, while other peptides secreted by the GI tract, including PYY, act as satiation signals. The ligands leptin, POMC, , CART, and BDNF,, the receptors for leptin, , melanocortins,– and BDNF, and the enzyme PC1, have been found to have function-altering mutations associated with obesity in children. Mutations in the ligands and receptors for NPY, AGRP, CPE,, and MCH have been found to alter energy balance in rodents, but have not been as convincingly shown to be associated with human obesity. Lines with arrowheads indicate stimulatory action. Lines ending with a perpendicular end-block indicate inhibitory action. Abbreviations: GI, gastrointestinal; PYY, peptide YY, IR, insulin receptor; LR, leptin receptor, NPY, neuropeptide Y; AGRP, agouti-related protein; POMC, pro-opiomelanocortin; CART, cocaine-amphetamine related transcript; PC1, prohormone convertase 1; CPE, carboxypeptidase E; MSH, melanocyte stimulating hormone; TRH, thyrotropin-releasing hormone; MCH, melanin concentrating hormone; GABA, gamma amino butyric acid; BDNF, brain-derived neurotrophic factor; TrkB, tyrosine kinase receptor B.